APA aipamena

Chaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011). Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design.

Chicago Style aipamena

Chaft, Jamie E., Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, and Gregory J. Riely. Disease Flare After Tyrosine Kinase Inhibitor Discontinuation in Patients With EGFR-mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib – Implications for Clinical Trial Design. 2011.

MLA aipamena

Chaft, Jamie E., et al. Disease Flare After Tyrosine Kinase Inhibitor Discontinuation in Patients With EGFR-mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib – Implications for Clinical Trial Design. 2011.